Peramivir

Drug Profile

Peramivir

Alternative Names: ALPIVAB; BCX-1812; JNJ-2; PeramiFlu; Rapiacta; Rapivab; RWJ-270201

Latest Information Update: 07 Jun 2017

Price : $50

At a glance

  • Originator BioCryst Pharmaceuticals; University of Alabama
  • Developer BioCryst Pharmaceuticals; Green Cross; Shionogi
  • Class Acetamides; Antivirals; Carboxylic acids; Cyclopentanes; Guanidines; Small molecules
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype; Influenza virus infections

Most Recent Events

  • 05 Jun 2017 Peramivir receives priority review status for Influenza virus infections (In adolescents, In children) in USA
  • 05 Jun 2017 Planned Prescription Drug User Fee Act (PDUFA) date for Influenza virus infections (In adolescents, In children) in USA (IV) is 2017-09-30
  • 05 Jun 2017 The US FDA accepts sNDA for Peramivir for Influenza virus infections (In adolescents, In children) for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top